A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck Academic Article uri icon

Overview

MeSH Major

  • Activin Receptors, Type II
  • Antineoplastic Agents
  • Carcinoma, Squamous Cell
  • Head and Neck Neoplasms
  • Immunoglobulin Fc Fragments
  • Neoplasm Recurrence, Local
  • Recombinant Fusion Proteins

abstract

  • In an unselected, heavily pretreated population of patients with RM-SCCHN, dalantercept monotherapy resulted in a favorable safety profile but only modest dose-dependent activity, and it did not meet the primary efficacy objective of the study. Cancer 2016;122:3641-9. © 2016 American Cancer Society.

publication date

  • January 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.30317

PubMed ID

  • 27648727

Additional Document Info

start page

  • 3641

end page

  • 3649